Table 1 Correlation of clinicopathological parameters and TACC3 expression (n = 264)

Age (years)

 < 37

31

16 (51.6%)

15 (48.4%)

 ≥ 37

233

86 (36.9%)

147 (63.1%)

Figo stage

 I

186

66 (35.5%)

120 (64.5%)

 II

67

30 (44.8%)

37 (55.2%)

 III

8

3 (37.5%)

5 (62.5%)

 IV

3

3 (100.0%)

0 (0.0%)

Tumor size (cm)

 < 4.5

221

83 (37.6%)

138 (62.4%)

 ≥ 4.5

43

19 (44.2%)

24 (55.8%)

Histological type

 HPVA

239

86 (36.0%)

153 (64.0%)

 NHPVA

25

16 (64.0%)

9 (36.0%)

Differentiation

 Well

11

8 (72.7%)

3 (27.3%)

 Moderate

140

61 (43.6%)

79 (56.4%)

 Poor

113

33 (29.2%)

80 (70.8%)

Stromal invasion

 < 1/3

67

27 (40.3%)

40 (59.7%)

 1/3–2/3

81

24 (29.6%)

57 (70.4%)

 ≥ 2/3

116

50 (43.1%)

66 (56.9%)

Nerve invasion

 Negative

238

85 (35.7%)

153 (64.3%)

 Positive

26

17 (65.4%)

9 (34.6%)

LVI

 None (0)

180

73 (40.6%)

107 (59.4%)

 Focal (1–4)

53

19 (35.8%)

34 (64.2%)

 Moderate (5–9)

18

6 (33.3%)

12 (66.7%)

 Extensive (≥ 10)

13

4 (30.8%)

9 (69.2%)

LNM

 Negative

204

76 (37.3%)

128 (62.7%)

 Positive

60

26 (43.3%)

34 (56.7%)

Parametrium invasion

 Negative

242

89 (36.8%)

153 (63.2%)

 Positive

22

13 (59.1%)

9 (40.9%)

Surgical margin

 Negative

244

89 (36.5%)

155 (63.5%)

 Positive

20

13 (65.0%)

7 (35.0%)

HPV subtype

 HPV 16

67

19 (28.4%)

48 (71.6%)

 HPV 18

72

25 (34.7%)

47 (65.3%)

 Other subtypes

18

8 (44.4%)

10 (55.6%)

 Not available

1

0 (0.0%)

1 (100.0%)

 Negative

106

50 (47.2%)

56 (52.8%)

MMR

 dMMR

20

10 (50.0%)

10 (50.0%)

 pMMR

244

92 (37.7%)

152 (62.3%)

P16

 Negative

24

20 (83.3%)

4 (16.7%)

 Positive

240

82 (34.2%)

158 (65.8%)

Ki67

 < 12.5

65

35 (53.8%)

30 (46.2%)

 ≥ 12.5

199

67 (33.7%)

132 (66.3%)